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INTRODUCTION:
Over the past 30 years greater attention has been focused 
on development of controlled and sustained drug delivery 
systems. Amongst the extensive research has been carried 
in designing of polymeric drug delivery systems. The 
development of in situ gel systems has received 
considerable attention over the past few years. In the past 
few years, increasing number of in situ gel forming 
systems have been investigated and many patents for their 
use in various biomedical applications including drug 
delivery have been reported. This interest has been sparked 
by the advantages shown by in situ forming polymeric 
delivery systems such as ease of administration and 
reduced frequency of administration, improved patient 
compliance and comfort1. In situ gel formulations offers an 
interesting alternative for achieving systemic drug effects 
of parenteral routes, which can be inconvenient or oral 
route, which can result in unacceptably low bioavailability 
and passes the hepatic first-pass metabolism, in particular 
of proteins and peptides2. This novel drug delivery system 
promotes the importantly ease and convenience of 
administration, deliverance of accurate dose as well as to 
prolong residence time of drug in contact with mucosa, 
that problems generally encountered in semisolid dosage 
forms. In situ gel formation occurs due to one or 
combination of different stimuli like pH change, 
temperature modulation and solvent exchange3. Smart 
polymeric systems represent promising means of 
delivering the drugs; these polymers undergo sol-gel 
transition, once administered. From the early 1970's 
natural and synthetic polymers began to be investigated for 
controlled release formulations. The advantages of using 
biodegradable polymers in clinical applications are 
apparent. Various natural and synthetic polymers are used 
for formulation development of in situ forming drug 
delivery systems4. This review attempts to discuss the 
newer developments and strategies for this drug delivery 
including physiological factors, physiochemical factors 
and formulation factors to be considered in the 
development of in-situ drug delivery system. Also, 
different types of smart polymers, their mechanisms of gel 
formation from the sol forms, evaluation and 
characterization of in situ polymeric formulations and 
commercial formulation are discussed.
IN SITU GELLING SYSTEM:-
This is a more desirable dosage form which can be deliver 
drug in solution form & create little to no problem of 
vision & frequently doses are not needed. This in situ 
gelling system is when exposed to physiological condition 
will shift to a gel phase. This new concept of production a 
gel in-situ was suggested first time in the early 
1980s.Gelation occurs via the cross linking of polymer 
chain that can be achieved covalent bond formation ( 
chemical cross linking ) or non covalent bond formation 
(physical cross linking)5. This system described as low 
viscosity solution that undergoes phase transition in 
conjuctival cul-de-sac to form viscoelestic gel due to 
conformational changes of polymer in response to 
physiological environment6. The rate of in situ gel 
formation is important because between instillation in eye 
& before a strong gel is formed; the solution or weak gel is 
produced by the fluid mechanism of eye7. 
ABSTRACT: 
In situ forming polymeric formulations are drug delivery systems that are in sol form before administration in the body, but once 
administered, undergo gelation in situ, to form a gel. The formation of gels depends on factors like temperature modulation, pH 
change, presence of ions and ultra violet irradiation, electrical sensitivity, enzyme sensitive from which the drug gets released in a 
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chitosan, poly (DL lactic acid), poly (DL-lactide-co-glycolide) and poly-caprolactone. The in situ gel forming polymeric 
formulations offer several advantages like sustained and prolonged action in comparison to conventional drug delivery systems
and good patient compliance, good stability and biocompatibility characteristics make the in situ gel dosage forms very reliable. 
Evaluation of In situ gel systems include in vitro drug release studies, sol-gel transition temperature and gelling time, gel strength, 
viscosity & rheology, texture analysis, clarity. Commercial formulations of in situ polymeric systems are Regel Depot 
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IMPORTANCE OF IN SITU GELLING SYSTEM:-
 The major importance is the possibilities of 
administrating accurate &reproducible quantities 
compared to already formed gel8.
 In-situ forming polymeric delivery system such as 
ease of administration &reduced frequency of 
administration improved patient compliance & 
comfort9.
 Poor bioavailability & therapeutic response exhibited 
by conventional ophthalmic solution due to rapid 
precorneal elimination of drug may be overcome by 
use of gel system that are instilled as drops into eye 
&undergoes a sol-gel transition from instilled dose10.
 Liquid dosage form that can sustain drug release & 
remain in contact with cornea of eye for extended 
period of time is ideal11.
 Reduced systemic absorption of drug drained through 
the nasolacrimal duct may result in some undesirable 
side effects12, 13.
IDEAL CHARACTERISTICS OF POLYMERS14:-
A polymer used to in situ gels should have following 
characteristics-
 It should be biocompatible.
 It should be capable of adherence to mucus.
 It should have pseudo plastic behaviour.
 It should be good tolerance & optical activity.
 It should influence the tear behaviour.
 The polymer should be capable of decrease the 
viscosity with increasing shear rate there by offering 
lowered viscosity during blinking & stability of the tear 
film during fixation.
The first use of gel for medical preparation was 
represented by Wichterle & Lim in 1960 in
manufacturing of soft contact lenses & implant material 
from Hydroxyethyl Methacrylate polymer15.
POLYMERS USED IN IN SITU GELLING SYSTEM
Gellangum
Gellan gum (commercially available as Gelrite TM or 
Kelcogel TM ) is an anionic deacetylated exocellular 
polysaccharide secreted by Pseudomonas elodea with a 
tetrasaccharide repeating unit of one α-L-rhamnose, one β-
D-glucuronic acid and two β-D-glucuronic acid residues16. 
It has the tendency of gelation which is temperature 
dependent or cations induced. This gelation involves the 
formation of double helical junction zones followed by 
aggregation of the double helical segments to form a three-
dimensional network by complexation with cations and 
hydrogen bonding with water17. The formulation consisted 
of gellan solution with calcium chloride and sodium citrate 
complex. When administered orally, the calcium ions are 
released in acidic environment of stomach leading to 
gelation of gellan thus forming a gel in situ18. In situ
gelling gellan formulation as vehicle for oral delivery of 
theophylline is reported.
Xyloglucan
Xyloglucan is a polysaccharide derived from tamarind 
seeds and is composed of a (1-4)-β-D-glucan backbone
chain, which has (1-6)-α-D xylose branches that are 
partially substituted by (1-2)-β-D-galactoxylose19. When 
xyloglucan is partially degraded by β- galactosidase, the 
resultant product exhibits thermally reversible gelation by 
the lateral stacking of the rod like chains. The sol-gel 
transition temperature varies with the degree of galactose 
elimination. It forms thermally reversible gels on warming 
to body temperature. Its potential application in oral 
delivery exploits the proposed slow gelation time (several 
minutes) that would allow in-situ gelation in the stomach 
following the oral administration of chilled xyloglucan 
solution20. Xyloglucan gels have potentially been used for 
oral, intraperitoneal, ocular and rectal drug delivery21, 22.
Alginic acid
Alginic acid is a linear block copolymer polysaccharide 
consisting of β-D-mannuronic acid and α-L-glucuronic 
acid residues joined by 1, 4-glycosidic linkages. The 
proportion of each block and the arrangement of blocks 
along the molecule vary depending on the algal source. 
Dilute aqueous solutions of alginates form firm gels on 
addition of di and trivalent metal ions by a cooperative 
process involving consecutive glucuronic residues in the α-
Lglucuronic acid blocks of the alginate chain23. Alginic 
acid can be chosen as a vehicle for ophthalmic 
formulations, since it exhibits favorable biological 
properties such as biodegradability and nontoxicity. A 
prolonged precorneal residence of formulations containing 
alginic acid was looked for, not only based on its ability to 
gel in the eye, but also because of its mucoadhesive 
properties24.
Xanthum gum
Xanthan gum is a high molecular weight extra cellular 
polysaccharide produced by the fermentation of the gram-
negative bacterium Xanthomonas campestris. The primary 
structure of this naturally produced cellulose derivative 
contains a cellulosic backbone (β- D-glucose residues) and 
a trisaccharide side chain of β-D-mannose-β-D-glucuronic 
acid-α-D-mannose attached with alternate glucose residues 
of the main chain. The anionic character of this polymer is 
due to the presence of both glucuronic acid and pyruvic 
acid groups in the side chain25.
Chitosan
Chitosan is a biodegradable, thermosensitive, polycationic 
polymer obtained by alkaline deacetylation of chitin, a 
natural component of shrimp and crab shell. Chitosan is a 
biocompatible pH dependent cationic polymer, which 
remains dissolved in aqueous solutions up to a pH of 6.226. 
Neutralization of chitosan aqueous solution to a pH 
exceeding 6.2 leads to the formation of a hydrated gel like 
precipitate. The pH gelling cationic polysaccharides 
solution are transformed into thermally sensitive pH 
dependent gel forming aqueous solutions, without any 
chemical modification or cross linking by addition of 
polyol salts bearing a single anionic head such as glycerol, 
sorbitol, fructose or glucose phosphate salts to chitosan 
aqueous solution27.
Carbopol
Carbopol is a well known pH dependent polymer, which 
stays in solution form at acidic pH but forms a low 
viscosity gel at alkaline pH. HPMC is used in combination 
with carbopol to impart the viscosity to carbopol solution, 
while reducing the acidity of the solution. Various water 
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soluble polymers such as carbopol system-
hydroxypropylmethylcellulose system, poly (methacrylic 
acid)-poly (ethylene glycol) come under the category of 
pH-induced in-situ precipitating polymeric systems. Based 
on this concept, the formulation and evaluation of an 
ophthalmic delivery system for indomethacin for the 
treatment of uveitis was carried out. A sustained release of 
indomethacin was observed for a period of 8 h in vitro thus 
considering this system as an excellent candidate for 
ocular delivery. A pH induced in-situ precipitating 
polymeric system (an aqueous solution of carbopol-HPMC 
system) was designed and developed by Ismail et al. for 
plasmid DNA delivery28.
Pectin
Pectins are a family of polysaccharides, in which the 
polymer backbone mainly comprises α-(1-4) D 
galacturonic acid residues. Low methoxy pectins (degree 
of esterification <50%) readily form gels in aqueous 
solution in the presence of free calcium ions, which 
crosslink the galacturonic acid chains in a manner 
described by egg-box model. Although the gelation of 
pectin will occur in the presence of H + ions, a source of 
divalent ions, generally calcium ions is required to produce 
the gels that are suitable as vehicles for drug delivery29. 
The main advantage of using pectin for these formulations 
is that it is water soluble, so organic solvents are not 
necessary in the formulation. Divalent cations present in 
the stomach, carry out the transition of pectin to gel state 
when it is administered orally. Calcium ions in the 
complexed form may be included in the formulation for 
the induction of pectin gelation30. Sodium citrate may be 
added to the pectin solution to form a complex with most 
of calcium ions added in the formulation. By this means, 
the formulation may be maintained in a fluid state (sol), 
until the breakdown of the complex in the acidic 
environment of the stomach, where release of calcium ions 
causes gelation to occur. The quantities of calcium and 
citrate ions may be optimized to maintain the fluidity of 
the formulation before administration and resulting in 
gelation, when the formulation is administered in stomach. 
The potential of an orally administered in situ gelling 
pectin formulation for the sustained delivery of 
Paracetamol has been reported4.
Pluronic F-127
Poloxamers or pluronic (marketed by BASF Corporation) 
are the series of commercially available difunctional 
triblock copolymers of non-ionic nature. They comprise of 
a central block of relatively hydrophobic polypropylene 
oxide surrounded on both sides by the blocks of relatively 
hydrophilic poly ethylene oxide31. Due to the PEO/PPO 
ration of 2:1, when these molecules are immersed into the 
aqueous solvents, they form micellar structures above 
critical micellar concentration. They are regarded as PEO-
PPO-PEO copolymers. Chemically they are Oxirane, 
methyl-, polymer with oxirane or α-Hydro-ω- hydroxypoly 
(oxyethylene) a poly (oxypropylene) b poly (oxyethylene) 
a block copolymer. The pluronic triblock copolymers are 
available in various grades differing in molecular weights 
and physical forms. Depending upon the physical 
designation for the grades are assigned, as F for flakes, P 
for paste, L for liquid. Pluronics or Poloxamers also 
undergo in situ gelation by temperature change. They are 
triblock copolymers consisting of poly (oxyethylene) and 
poly (oxypropylene) units that undergo changes in 
solubility with change in environment temperature. 
Pluronic ™ F 127. A 25-40% aqueous solution of this
material will gel at about body temperature, and drug 
release from such a gel occurs over a period of up to one 
week32. Pluronic F-127 was used as an in situ gel forming 
polymer together with mucoadhesive polymers such as 
Carbopol 934 and hydroxylpropylmethylcellulose to 
ensure long residence time at the application site. 
Controlled release of drug was achieved in-vitro indicating 
antimycotic efficacy of developed formulation for a longer 
period of time33.
Synthetic polymers
Synthetic polymers are popular choice mainly for 
parenteral preparations. The trend in drug delivery 
technology has been towards biodegradable polymers, 
requiring no follow up surgical removal, once the drug 
supply is depleted. Aliphatic polyesters such as poly (lactic 
acid), poly (glycolic acid), poly (lactide- coglycolide), poly 
(decalactone), poly ε-caprolactone have been the subject of 
the most extensive recent investigations. Synthetic 
polymers are popular choice mainly for parenteral 
preparations. The trend in drug delivery technology has 
been towards biodegradable polymers, requiring no follow 
up surgical removal, once the drug supply is depleted. 
Aliphatic polyesters such as poly (lactic acid), poly 
(glycolic acid), poly (lactide- coglycolide), poly 
(decalactone), poly ε-caprolactone have been the subject of 
the most extensive recent investigations26. Various other 
polymers like triblock polymer systems composed of 
poly(D,L-lactide)-block-poly(ethylene glycol)-block-
poly(DL-lactide), blends of low molecular weight 
poly(D,L-lactide) and poly(ε- caprolactone) are also in use. 
These polymers are mainly used for the injectable in situ 
formulations. The feasibility of lactide/glycolide polymers 
as excipients for the controlled release of bioactive agents 
is well proven. These materials have been subjected to 
extensive animal and human trials without evidence of any 
harmful side effects. When properly prepared under GMP 
conditions from purified monomers, the polymers exhibit 
no evidence of inflammatory response or other adverse 
effects upon implantation34. Another type of synthetic 
polymeric system includes the in situ cross linked system, 
where the polymers form cross linked networks by means 
of free radical reactions that may occur by means of light 
(photopolymerizable systems) or heat(thermosetting 
systems).
Thermosetting systems are in the sol form when initially 
constituted, but upon heating, they set into their final 
shape. This sol-gel transition is known as curing. But if
this cured polymer is heated further, it may lead to 
degradation of the polymer. Curing mainly involves the 
formation of covalent cross links between polymer chains 
to form a macromolecular network. Dunn et al. designed a 
thermosetting system using biodegradable copolymers of 
DL-lactide or L-lactide with ε-caprolactone for prosthetic 
implant and slow release drug delivery systems. This 
system is liquid outside the body and is capable of being 
injected by a syringe and needle and once inside the body, 
it gels. In in situ precipitating polymeric systems, the 
polymer precipitation from solution may lead to gel 
formation in situ and this precipitation can be induced by 
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change in temperature (thermosensitive systems), solvent 
removal or by change in pH35. An important example of 
thermosensitive polymer is poly-(N-isopropyl acrylamide), 
[poly (NIPAAM)], which is used for the formation of in 
situ gels. It has lower critical solution temperature phase 
separation at about 32. The polymers such as poly (DL-
lactide), poly (DL-lactide-co-glycolide) and poly (DL-
lactide-co-Ξ-caprolactone) form solvent-removal 
precipitating polymeric systems36.
APPROACHES OF IN SITU GEL DRUG DELIVERY
There are four broadly defined mechanisms used for 
triggering the in situ gel formation of biomaterials:
Physiological stimuli (e.g., temperature and pH), physical 
changes in biomaterials (e.g., solvent exchange and 
swelling), chemical reactions (e.g., enzymatic, chemical 
and photo-initiated polymerization).
In situ formation based on physiological stimuli:
Temperature  triggered system–
Temperature-sensitive hydrogels are probably the most 
commonly studied class of environment-sensitive polymer 
systems in drug delivery research37. The use of biomaterial 
whose transitions from sol-gel is triggered by increase in 
temperature is an attractive way to approach in-situ 
formation. The ideal critical temperature range for such 
system is ambient and physiologic temperature, such that 
clinical manipulation is faccilated and no external source 
of heat other than that of body is required for trigger
gelation. A useful system should be tailorable to account 
for small differences in local temperature, such as might be 
encountered in appendages at the surface of skin or in the 
oral cavity. Three main strategies are exists in engineering 
of thermoresponsive sol-gel polymeric system. For 
convenience, temperature-sensitive hydrogels are 
classified into negatively thermosensitive, positively 
thermosensitive, and thermally reversible gels (1, 3).
Negative temperature-sensitive hydrogels have a lower 
critical solution temperature (LCST) and contract upon 
heating above the LCST. Polymers with low critical 
temperature (LCST) transition between ambient and 
physiologic temperature is used for this purpose. One of 
the most extensively investigated polymers that exhibit 
useful LCST transition is poly (Nisopropylacrylamide) 
(PNIPAAm). PNIPAAm is a water soluble polymer at its 
low LCST, but hydrophobic above LCST, which result on 
precipitation of PNIPAAm from the solution at the LCST. 
Pluronics are poly (ethylene oxide)-poly (propylene 
oxide)-poly (ethylene oxide) (PEO-PPOPEO) triblock co-
polymer that are fluid at low temperature, but forms 
thermo responsible gel when heated as a consequences of a 
disorder-order transition in micelle packing which makes 
these polymers suitable for in situ gelation38. A positive 
temperaturesensitive hydrogel has an upper critical 
solution temperature (UCST), such hydrogel contracts 
upon cooling below the UCST. Polymer networks of poly 
(acrylic acid) (PAA) and polyacrylamide (PAAm) or poly 
(acrylamide-co-butyl methacrylate) have positive 
temperature dependence of swelling39. The most 
commonly used thermoreversible gels are these prepared 
from poly (ethylene oxide)-b-poly (propylene oxide)-b
poly (ethylene oxide) (Pluronics®, Tetronics®, 
poloxamer). Polymer solution is a free flowing liquid at 
ambient temperature and gels at body temperature40. 
Cappello et al. developed novel “protein polymers” 
ProLastins, which undergo an irreversible sol gel 
transition. When injected as a solution into the body, the 
material forms a firm, stable gel within minutes. It remains 
at the site of injection providing absorption times from less 
than one week to many months. Such a system would be 
easy to administer into desired body cavity41.
pH triggered systems -
Another formation of in situ gel based on physiologic 
stimuli is formation of gel is induced by pH changes37. All 
the pH-sensitive polymers contain pendant acidic or basic 
groups that either accept or release protons in response to 
changes in environmental pH .The polymers with a large 
number of ionizable groups are known as polyelectrolytes. 
Swelling of hydrogel increases as the external pH 
increases in the case of weakly acidic (anionic) groups, but 
decreases if polymer contains weakly basic (cationic) 
groups39. The most of anionic pH-sensitive polymers are 
based on PAA (Carbopol®, carbomer) or its derivatives42. 
Likewise polyvinylacetal diethylaminoacetate (AEA) 
solutions with a low viscosity at pH 4 form hydrogel at 
neutral pH condition43. Drug formulated in liquid solutions 
have several limitations, including limited bioavailability 
and propensity to be easily removed by tear fluid. Kumar 
and Himmelstein sought to minimize this factor and 
maximize this drug delivery by making a poly (acrylic 
acid) (PAA) solution that would be gel at pH 7.4.The 
author found that at concentrations high enough to cause 
gelation, however, the low pH of PAA solution would 
cause damage to surface of eye before being neutralized by 
the lacrimal fluid. This problem was solved by partially by 
combining PAA with HPMC, a viscous enhancing 
polymer, which resulted in pH responsive polymer 
mixtures that was sol at pH 4 and gel at pH 7.444. Mixtures 
of poly (methacrylic acid) (PMA) and poly (ethylene 
glycol) 
(PEG) also has been used as a pH sensitive system to 
achieve gelation45.
In situ formation based on physical mechanism-
Swelling 
In situ formation may also occur when material absorbs 
water from surrounding environment and expand to occur 
desired space46. One such substance is myverol 18-99 
(glycerol mono-oleate), which is polar lipid that swells in 
water to form lyotropic liquid crystalline phase structures. 
It has some Bioadhesive properties and can be degraded in 
vivo by enzymatic action47.
Diffusion
This method involves the diffusion of solvent from 
polymer solution into surrounding tissue and results in
precipitation or solidification of polymer matrix. Nmethyl 
pyrrolidone (NMP) has been shown to be useful solvent 
for such system48.
In situ formation based on chemical reactions
Chemical reactions that results in situ gelation may involve 
precipitation of inorganic solids from supersaturated ionic 
solutions, enzymatic processes, and photo-initiated 
processes.
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Ionic crosslinking
Polymers may undergo phase transition in presence of 
various ions. Some of the polysaccharides fall into the 
class of ion-sensitive ones49. While k-carrageenan forms 
rigid, brittle gels in reply of small amount of K+, i-
carrageenan forms elastic gels mainly in the presence of 
Ca2+. Gellan gum commercially available as Gelrite® is 
an anionic polysaccharide that undergoes in situ gelling in 
the presence of mono- and divalent cations, including 
Ca2+, Mg2+, K+ and Na+. Gelation of the low-methoxy 
pectins can be caused by divalent cations, especially Ca2+. 
Likewise, alginic acid undergoes gelation in presence of 
divalent/polyvalent cations e. g. Ca2+ due to the 
interaction with glucuronic acid block in alginate chains50.
Enzymatic cross-linking
In situ formation catalysed by natural enzymes has not 
been investigated widely but seems to have some 
advantages over chemical and photochemical approaches. 
For example, an enzymatic process operates efficiently 
under physiologic conditions without need for potentially 
harmful chemicals such as monomers and initiators. 
Intelligent stimuli-responsive delivery systems using 
hydrogels that can release insulin have been investigated. 
Cationic pH-sensitive polymers containing immobilized 
insulin and glucose oxidase can swell in response to blood 
glucose level releasing the entrapped insulin in a pulsatile 
fashion. Adjusting the amount of enzyme also provides a 
convenient mechanism for controlling the rate of gel 
formation, which allows the mixtures to be injected before 
gel formation51.
Photo-polymerisation-
Photo-polymerisation is commonly used for in situ 
formation of biomaterials. A solution of monomers or
reactive macromer and initiator can be injected into a
tissues site and the application of electromagnetic radiation 
used to form gel37. Acrylate or similar polymerizable 
functional groups are typically used as the polymerizable 
groups on the individual monomers and macromers 
because they rapidly undergo photo-polymerisation in the 
presence of suitable photo- initiator. Typically long 
wavelength ultraviolet and visible wavelengths are used. 
Short wavelength ultraviolet is not used often because it 
has limited penetration of tissue and biologically harmful. 
A ketone, such as 2, 2 dimethoxy-2-phenyl acetophenone, 
is often used as the initiator for ultraviolet photo-
polymerization, where as camphor quinone and ethyl eosin 
initiators are often used in visible light systems. These 
systems can be designed readily to be degraded by 
chemical or enzymatic processes or can be designed for 
long term persistence in vivo52. Photopolymerizable 
systems when introduced to the desired site via injection 
get photo cured in situ with the help of fiber optic cables 
and then release the drug for prolonged period of time. The 
photo-reactions provide rapid polymerization rates at 
physiological temperature. Furthermore, the systems are 
easily placed in complex shaped volumes leading to an 
implant formation. A photopolymerizable, biodegradable 
hydrogel as a tissue contacting material and controlled 
release carrier is reported by Sawhney et al53.
FORMULATION DESIGN
The design of in-situ gel formulation depends on the 
physicochemical properties of the drug molecule, the
diseased condition for which treatment is required, the 
patient population and the marketing preference. Physico-
chemical factors include molecular weight, lipophilicity 
and molecular charge; an anatomical and physiological 
factor includes membrane transport, pH of tissue fluid, and 
mucocilliary clearance (as in case of nasal 
administrations). While formulation factors include clarity, 
pH, gelation temperature, viscosity, osmolarity, 
spreadability3.
APPLICABILITY OF IN SITU POLYMERIC DRUG 
DELIVERY
SYSTEM:-
Oral drug delivery system:-
The pH-sensitive hydrogels have a potential use in site-
specific delivery of drugs to specific regions of the GI 
tract. Hydrogels made of varying proportions of PAA 
derivatives and crosslinked PEG allowed preparing 
silicone microspheres, which released prednisolone in the 
gastric medium or showed gastroprotective property54. 
Cross-linked dextran hydrogels with a faster swelling 
under high pH conditions, likewise other polysaccharides 
such as amide pectins, guar gum and insulin were 
investigated in order to develop a potential colon-specific 
drug delivery system. W. Kubo et al.55 developed the 
formulations of gellan and sodium alginate both containing 
complexed calcium ions that undergo gelation by releasing 
of these ions in the acidic environment of the stomach. 
Oral delivery of paracetamol was studied.
For the oral in situ gel delivery system pectin, xyloglucan 
& gellan gum natural polymers are used. Pectin 
formulation for sustained delivery of paracetamol has been 
reported56. Advantages of pectin is water soluble so, no 
need to add organic solvent.
Ocular drug delivery system:-
In ocular delivery system natural polymers like gallan 
gum, alginic acid & xyloglucan are most commonly used. 
For local ophthalmic delivery system various compounds 
like antimicrobial agent, anti-inflammatory agent & 
autonomic drugs are used to relieve intra ocular tension in 
glaucoma. Conventional delivery system often result in 
poor availability & therapeutic response because high tear 
fluid turn over & dynamics which cause rapid elimination 
of the drug from the eye so, the overcome the 
bioavailability problem ophthalmic in-situ gel was 
developed57. 
To improve the bioavailability viscosity enhancers such as 
Hydroxy Propyl Methyl Cellulose, Carboxy Methyl 
Cellulose, Carbomers, Poly Vinyl alcohol used to increase 
the viscosity of formulation in order to prolong the 
precorneal residence time & improve the bioavailability, 
ease to manufacture. Penetration enhancer such as 
preservatives, chelating agent, surfactants are used to 
enhance corneal drug penetration58.
Nasal drug delivery system:-
In nasal in-situ gel system gallan gum & xanthan gum are 
used as in-situ gel forming polymers Momethasone furoate 
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was evaluated for it‘s efficacy for the treatment of allergic 
rhinitis59. Animal study were conducted using allergic 
rhinitis model & effect of in-situ gel on antigen induced 
nasal symptoms in sensitizes rats was observed. In-situ gel 
was found to inhibit the increase in nasal symptoms are 
compared to marketed preparation nosonex (Momethasone 
furoate suspension 0.05%).
Rectal drug delivery system:-
The rectal route may be used to deliver many types of 
drugs that are formulated as liquid, semisolid (ointments, 
creams and foams) and solid dosage forms (suppositories). 
Conventional suppositories often cause discomfort during 
insertion. In addition, suppositories are unable to be 
sufficiently retained at a specific position in the rectum, 
sometimes they can migrate up-wards to the colon that 
makes them possible for drug to undergo the first-pass 
effect. Choi et al.60 developed novel in situ gelling liquid 
suppositories with gelation temperature at 30–36°C. 
Poloxamer 407 and/ or poloxamer 188 were used to confer 
the temperature-sensitive gelation property.
In-situ gel possesses a potential application for rectal & 
vaginal route .Miyazaki et al. investigated the use of 
xyloglucan based thermo reversible gel for rectal drug 
delivery of Indomethacin. Administration of indomethacin 
loaded xyloglucan based system to rabbit indicated broad 
drug absorption & a longer drug residence time as 
compared to that resulting after administration of 
commercial suppository. For better therapeutic efficacy & 
patient compliance, mucoadhesive, thermo sensitive, 
prolonged release vaginal gel incorporating Clotrimazole-
β-cyclodextrin complex formulated for treatment of 
vaginitis61.
Vaginal drug delivery system:-
The vagina, in addition to being an important organ of 
reproductive tract, serves as a potential route for drug 
administration. Formulations based on a thermo-plastic 
graft copolymer that undergo in situ gelation have been 
developed to provide the prolonged release of active 
ingredients such as nonoxynol-9, progestins, estrogens, 
peptides and proteins62. Chang et al.63 have recently 
reported a mucoadhesive thermo-sensitive gel 
(combination of poloxamers and polycarbophil), which 
exhibited, increased and prolonged antifungal activity of 
clotrimazole in comparison with conventional PEG-based 
formulation.
Injectable drug delivery system:-
One of the most obvious ways to provide sustained-
release medication is to place the drug in delivery system 
and inject or implant the system into the body tissue. 
Thermoreversible gels mainly prepared from poloxamers 
are predominantly used64. The suitability of poloxamer gel 
alone or with the addition of 
hydroxypropylmethylcellulose (HPMC), sodium 
carboxymethylcellulose (CMC) or dextran was studied for 
epidural administration of drugs in vitro65. The compact 
gel depot acted as the rate limiting step and significantly 
prolonged the dural permeation of drugs in comparison 
with control solutions. J. M. Barichello et al.66 evaluated 
Pluronic F127 gels, which contained either insulin or 
insulin-PLGA nanoparticles with conclusion, that these 
formulations could be useful for the preparation of a 
controlled delivery system. Likewise, poloxamer gels were 
tested for intramuscular and subcutaneous administration 
of human growth hormone67 or with the aim to develop a 
long acting single dose injection of lidocaine64. J. R. 
DesNoyer and A. J. McHugh68 invented a new class of 
injectable controlled release depots of protein which 
consisted of blends of Pluronics with poly (D, L-lactide)/1-
methyl-2- pyrrolidone solutions. Some other 
thermosensitive hydrogels may also be used for parenteral 
administration. ReGel ® (triblock copolymer PLGAPEG-
PLGA) was used as a drug delivery carrier for the 
continuous release of human insulin69. Steady amounts of 
insulin secretion from the Re- Gel ® formulations up to 
day 15 of the subcutaneous injections were achieved. B. 
Jeong et al.70 reported the synthesis of a biodegradable 
poly (ethylene oxide) and poly (L-lactic acid) hydrogel, 
which exists in a form of sol at an elevated temperature 
(around 45°C) and forms a gel after subcutaneous injection 
and subsequent rapid cooling to body temperature. In-situ 
forming Injectable drug delivery system, cross linking of 
hydrazide modified by aluronic acid with aldehyde 
modified version of cellulose derivatives such as carboxy 
methyl cellulose, methyl cellulose, hydroxy propyl methyl 
cellulose are used. These in-situ forming gel were used for 
preventing postoperative peritoneal adhesion thus avoiding 
pelvic pain, bowel obstruction & infertility. For a better 
therapeutic efficacy & patient compliance, mucoadhesive, 
thermo sensitive, prolonged release vaginal gel 
incorporating Clotrimazole-β-cyclodextrin complex was 
formulated for treatment of virginities71.
Dermal and transdermal drug delivery system:-
Thermally reversible gel of Pluronic F127 was evaluated 
as vehicle for the percutaneous administration of 
Indomethacin72. In-vivo studies suggest that 20% w/w 
aqueous gel may be of practical use as a base for topical 
administration of the drug. Poloxamer 407 gel was found 
suitable for transdermal delivery of insulin73. The 
combination of chemical enhancers and iontophoresis 
resulted in synergistic enhancement of insulin permeation.
EVALUATION AND CHARACTERIZATION OF IN 
SITU GELLING SYSTEM:-
In-situ gel evaluated & characterized by the following 
parameters-
Clarity:-
The clarity of formulated solution is determined by visual 
inspection under black & white Background74.
Texture analysis:-
The consistency, firmness &cohesiveness of in situ gel are 
assessed by using texture profile analyzer which mainly 
indicated gel strength & easiness in administration in vivo 
higher value of adhesiveness of gel are needed to maintain 
an intimate contact with mucus surface75.
pH of gel:-
pH can be determined formulation is taken in beaker & 
1ml NaOH added drop wise with continuous stirring.  pH 
is checked by using pH meter76.
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Sol-Gel transition temperature and gelling time
For in situ gel forming systems incorporating 
thermoreversible polymers, the sol-gel transition 
temperature may be defined as that temperature at which 
the phase transition of sol meniscus is first noted when 
kept in a sample tube at a specific temperature and then 
heated at a specified rate. Gel formation is indicated by a 
lack of movement of meniscus on tilting the tube. Gelling 
time is the time for first detection of gelation as defined 
above19.
Gel-Strength
This parameter can be evaluated using a rheometer. 
Depending on the mechanism of the gelling of gelling 
agent used, a specified amount of gel is prepared in a 
beaker, from the sol form. This gel containing beaker is 
raised at a certain rate, so pushing a probe slowly through 
the gel. The changes in the load on the probe can be 
measured as a function of depth of immersion of the probe 
below the gel surface19.
Gelling capacity:-
In-situ gel is mix with simulated tear fluid (in the 
proportion of 25:7 i.e. application volume 25μl & normal 
volume of tear fluid in eye is 7μl) to find out gelling 
capacity of ophthalmic product. The gelation assessed 
visually by noting the time for & time taken for dissolution 
of the formed gel77.
Rheological studies:-
The viscosity measured by using Brookfield viscometer, 
cone & plate viscometer. In-situ gel formulation is placed 
in sample tube. Formulation should have viscosity 5-1000 
mPas, before gelling & after ion gel activation by eye will 
have viscosity of from about 50-50,000 mPas77, 78.
Isotonicity evaluation:-
Isotonicity is important characteristics of ophthalmic 
preparation. Isotonicity is maintained to prevent tissue 
damage or irritation of eye. All ophthalmic preparation are 
subjected to isotonicity testing, science they exhibited 
good release characteristics & gelling capacity & the 
requite velocity. Formulation mixed with few drops of 
blood & observed under microscope at 45x magnification 
& compared with standard marketed ophthalmic 
formulation79.
Swelling studies:-
Swelling studies are conducted with a cell, equipped with 
thermo jacket to maintain a constant temperature .The cell 
contains artificial tear fluid (composition – 0.67g Nacl, 
0.20g NaHCo3, 0.008g Cacl2.2H2o & distilled water q.s to 
100g)80. swelling medium equilibrating at 370c one 
milliliter of formulated solution is placed in dialysis bag & 
put into the swelling medium. At specific time interval the 
bag is removed from the medium & weight is recorded. 
The swelling of the polymer gel as a function of time is 
determined by using the following relationship81, 82.
% St = (Wt – W0) 100/W0
Where,
St = Swelling at time‘t’.
W0=Initial weight of gelling solution.
Wt=Final weight of gel.
Statistical analysis:-
Analysis of variance (ANOVA) is used the testing the 
difference between calculated parameters using SPSS 
statistical package. Statistical difference yielding P≤0.05 is 
considered83. Duncan multiple comparison is applied when 
necessary to identify which of the individual formulations 
are significantly different84. 
High performance liquid chromatography:-
The HPLC system is used in reversed phase mode. 
Analysis is performed on a Nova pack C18 packed column 
(150 mm length X 3.9 mm i.d)85.
Fourier transformer infra red:-
The possibility of drug excipient interaction is investigated 
by FTIR studies. The FTIR graph of pure drug & 
combination of drug with excipient are recorded by using 
KBR pellets85, 86.
Thermal analysis:-
Thermo gravimetric analysis can be conducted for in situ 
forming polymeric system to quantitative the percentage of 
water in hydrogel. Different scanning calorimetry is used 
to observed, if there are many changes in thermograms as 
compared with pure ingredients used thus indicating the 
interaction87. 
In vitro drug release studies:-
In vitro release study of in situ gel solution is carried out 
by using Franz diffusion cell. The formulation is placed in 
donor compartment & freshly prepared simulated tear fluid 
in receptor compartment. Between receptor & donor 
compartment dialysis membrane is placed (0.22 μm pore 
size). The whole assembly is placed on thermostatically 
controlled magnetic stirrer. The temperature of the 
medium is maintained at 37ºc± 0.5ºc. 
1ml sample is withdrawn at predetermined time 
interval of 1hr for 6hrs the sample volume of fresh 
medium is replaced. The withdrawn sample is diluted to 
10ml in volumetric flask with respective solvent & 
analyzed by UV spectrophotometer at respective nm using 
reagent blank. The drug content calculated using an 
equation generated from standard calibration curve. The 
percentage cumulative drug release (% CDR) calculated. 
The obtained data is further subjected to curve fitting for 
drug release data. The best fit model is checked for 
Krosmeyers peppas & Fickinian diffusion mechanism of 
their kinetics88.
Ocular irritancy studies:-
Ocular irritancy studies are performed on male albino 
rabbits, weighing 1-2 kg. The modified Draize technique is 
used for ocular irritation potential of ophthalmic 
products89. The formulation is placed in lower cul-de-sac 
& irritancy is tested at time interval of 1hr, 2hrs, 48hrs, 
72hrs, & 1 week after administration90. The rabbits are 
observed periodically for redness, swelling, & watering of 
eyes91. 
Antimicrobial activity:-
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Antimicrobial efficacy studies are carried out to ascertain 
the biological activity of sol-gel-system against 
microorganisms. This is determined in agar diffusion 
medium employing ‘Cup Plate Techniques’92. The 
microbial growth of bacteria is measured by conc. Of 
antibiotic & compared with that produced by known conc. 
Of standard preparation of antibiotic & carried out the 
microbial assay serial dilution method is employed93, 94. 
Sterility testing:-
Sterility testing is carried out as per the IP 1996. The 
formulation is incubating for not less than 14 days at 300-
350c in the fluid thioglycolate medium to find the growth 
of bacteria & at 200-250 c in Soya bean casein digest 
medium to find the growth of fungi in formulation95.
Accelerated stability studies:-
Formulation is replaced in amber colored vials & sealed 
with aluminum foil for the short term accelerated stability 
study at 40± 20 c & 75 ±5% RH as per International 
Conference of Harmonization (ICH) State Guidelines. 
Sample is analyzed at every month for clarity, pH, gelling 
capacity, drug content, rheological evaluation & in vitro 
dissolution96. 
Histopathological studies
Two mucosa tissue pieces (3 cm2) were mounted on in 
vitro diffusion cells. One mucosa was used as control (0.6 
mL water) and the other was processed with 0.6 mL of 
optimized organogel (conditions similar to in vitro 
diffusion). The mucosa tissues were fixed in 10% neutral 
carbonate formalin (24 hours), and the vertical sections 
were dehydrated using graded solutions of ethanol. The 
subdivided tissues were stained with hematoxylin and 
eosin. The sections under microscope were photographed 
at original magnification ×100. The microscopic 
observations indicate that the organogel has no significant 
effect on the microscopic structure of the mucosa. The 
surface epithelium lining and the granular cellular structure 
of the nasal mucosa were totally intact. No major changes 
in the ultrastructure of mucosa morphology could be seen 
and the epithelial cells appeared mostly unchanged97.
COMMERCIAL FORMULATIONS OF IN-SITU 
POLYMERIC SYSTEMS AT A GLANCE
Regel: depot-technology
Regel is one of the Macromed's proprietary drug delivery 
system and based on triblock copolymer, composed of 
poly (lactide-co-glycolide)-poly (ethylene glycol)-poly 
(lactide-co-glycolide). It is a family of thermally reversible 
gelling polymers developed for parenteral delivery that 
offers a range of gelation temperature, degradation rates 
and release characteristics as a function of molecular 
weight, degree of hydrophobicity and polymer 
concentration. Following injection, the physical properties 
of polymer undergo a reversible phase change resulting in 
formation of a water insoluble, biodegradable gel depot. 
Oncogel is a frozen formulation of paclitaxel in Regel. It is 
a free flowing liquid below room temperature which upon 
injection forms a gel in-situ in response to body 
temperature. hGHD-1 is a novel injectable depot 
formulation of human growth hormone (hGH) utilizing 
Macromed's Regel drug delivery system for treatment of 
patients with hGHdeficiency98.
Cytoryn
This is one of the Macromed's products, which is a novel, 
peritumoral, injectable depot formulation of interleukin-2 
(IL-2) for cancer immunotherapy using Regel drug 
delivery system. It is a free flowing liquid below room 
temperature that instantly forms a gel depot upon injection 
from which the drug is released in a controlled manner. 
Cytoryn enhances the immunological response by safely 
delivering four times the maximum tolerated dose allowed 
by conventional IL-2 therapy. Cytoryn also activates the 
systemic antitumor immunity. Regel system stabilizes and 
releases IL-2 in its bioactive form. The release of drugs is 
controlled by the rate of diffusion from and degradation of 
the depot.
Timoptic-XE
It is a timolol maleate ophthalmic gel formulation of 
Merck and Co. Inc., supplied as a sterile, isotonic,
buffered, aqueous gel forming solution of timolol maleate. 
This formulation is available in two dosage strengths 
0.25% and 0.5% in market. The pH of the solution is 
approximately 7.0, and the osmolarity is 260-330 mOsm. 
Each ml of Timoptic-XE 0.25% contains 2.5 mg of timolol 
(3.4 mg of timolol maleate). Inactive ingredients include 
gellan gum, tromethamine, mannitol, and water for 
injection and the preservative used is benzododecinium 
bromide 0.012%. Timoptic- XE, when applied topically on 
the eye, reduces the elevated, as well as normal intraocular 
pressure, whether or not accompanied by glaucoma.
CONCLUSION
In conclusion, the primary requirement of a successful 
controlled release product focuses on increasing patient 
compliance which the in situ gel offers. Exploitation of 
polymeric in- situ gel for controlled release of various 
drugs provides a number of advantages over conventional 
dosage forms. Sustained and prolonged release of the drug, 
good stability and biocompatibility characteristics make 
the in situ gel dosage forms very reliable. Use of 
biodegradable and water soluble polymers for the in situ 
gel formulations can make them more acceptable and 
excellent drug delivery systems.
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